Get started
Ocugen, Inc.Ocugen, Inc.Ocugen, Inc.

Ocugen, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

OCGN chart


Full chart

OCGN upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪229.15 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.1757 USD
Net income (FY)
‪−63.08 M‬ USD
Revenue (FY)
‪6.04 M‬ USD
Shares float
‪286.08 M‬
Beta (1Y)
2.24

Employees


Employees (FY)
65
Change (1Y)
−19 −22.62%
Revenue / Employee (1Y)
‪92.86 K‬ USD
Net income / Employee (1Y)
‪−970.43 K‬ USD

About Ocugen, Inc.


Sector
Health Technology
CEO
Shankar Musunuri
Headquarters
Malvern
Website
ocugen.com
Founded
2013
FIGI
BBG00194VJB1
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

OCGN news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of OCGN is 0.7866 USD — it has decreased by −5.33% in the past 24 hours. Watch Ocugen, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Ocugen, Inc. stocks are traded under the ticker OCGN.
OCGN stock has fallen by −20.32% compared to the previous week, the month change is a −10.46% fall, over the last year Ocugen, Inc. has showed a 35.62% increase.
We've gathered analysts' opinions on Ocugen, Inc. future price: according to them, OCGN price has a max estimate of 8.00 USD and a min estimate of 4.00 USD. Watch OCGN chart and read a more detailed Ocugen, Inc. stock forecast: see what analysts think of Ocugen, Inc. and suggest that you do with its stocks.
OCGN reached its all-time high on Dec 3, 2014 with the price of 778.2000 USD, and its all-time low was 0.1700 USD and was reached on Jun 1, 2020. View more price dynamics on OCGN chart.
See other stocks reaching their highest and lowest prices.
OCGN stock is 7.42% volatile and has beta coefficient of 2.24. Track Ocugen, Inc. stock price on the chart and check out the list of the most volatile stocks — is Ocugen, Inc. there?
Today Ocugen, Inc. has the market capitalization of ‪229.15 M‬, it has decreased by −4.81% over the last week.
Yes, you can track Ocugen, Inc. financials in yearly and quarterly reports right on TradingView.
Ocugen, Inc. is going to release the next earnings report on Mar 28, 2025. Keep track of upcoming events with our Earnings Calendar.
OCGN earnings for the last quarter are −0.05 USD per share, whereas the estimation was −0.06 USD resulting in a 9.09% surprise. The estimated earnings for the next quarter are −0.06 USD per share. See more details about Ocugen, Inc. earnings.
Ocugen, Inc. revenue for the last quarter amounts to ‪1.14 M‬ USD, despite the estimated figure of ‪400.00 K‬ USD. In the next quarter, revenue is expected to reach ‪400.00 K‬ USD.
OCGN net income for the last quarter is ‪−12.97 M‬ USD, while the quarter before that showed ‪−15.28 M‬ USD of net income which accounts for 15.12% change. Track more Ocugen, Inc. financial stats to get the full picture.
No, OCGN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 12, 2025, the company has 65.00 employees. See our rating of the largest employees — is Ocugen, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Ocugen, Inc. EBITDA is ‪−50.89 M‬ USD, and current EBITDA margin is ‪−1.07 K‬%. See more stats in Ocugen, Inc. financial statements.
Like other stocks, OCGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ocugen, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Ocugen, Inc. technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Ocugen, Inc. stock shows the sell signal. See more of Ocugen, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.